Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

37.02
-0.2314-0.62%
Post-market: 36.99-0.0285-0.08%16:10 EDT
Volume:549
Turnover:20.33K
Market Cap:19.43M
PE:- -
High:37.03
Open:37.03
Low:36.99
Close:37.25
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.77
T/O Rate:0.10%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
34 mins ago

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Yesterday

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

TIPRANKS
·
Yesterday

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

GlobeNewswire
·
Yesterday

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Generate Steady Cash

TIPRANKS
·
Sep 19

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19

Electra Therapeutics indicated to open at $20, IPO priced at $15

TIPRANKS
·
Sep 18

Tellgen Corporation's Subsidiaries Obtain Regulatory Approvals for Two Diagnostic Products

Stock News
·
Sep 18

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Merck Says EU CHMP Backs Keytruda-Padcev Perioperative Use in Resectable Muscle-Invasive Bladder Cancer

Reuters
·
Sep 18

Merck & Co - Final Ec Decision Expected by Q4 2026

THOMSON REUTERS
·
Sep 18

Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Padcev® (Enfortumab Vedotin-Ejfv) as Perioperative Treatment for Adults with Resectable Muscle-Invasive Bladder Cancer (Mibc)

THOMSON REUTERS
·
Sep 18

Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living with Hiv

THOMSON REUTERS
·
Sep 18

All 50 States Sign up for Trump's Medicaid Most-Favored-Nation Plan

Reuters
·
Sep 18